SCHEMBL525722

SCHEMBL525722

NC(=S)Nc1cccnc1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.57
TP53 P04637 1/20 0.57
TYR P14679 1/20 0.57
TSHR P16473 1/20 0.57
TAS2R38 P59533 1/20 0.57
HSD17B10 Q99714 1/20 0.57
ATG4B Q9Y4P1 1/20 0.56
MAPT P10636 1/20 0.56
PKM P14618 2/20 0.55
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
KDM4E B2RXH2 1/20 0.54
LMNA P02545 1/20 0.53
HIF1A Q16665 1/20 0.53
KMT2A Q03164 1/20 0.53
NAMPT P43490 1/20 0.51
HPGD P15428 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29972743 1.00 ALDH1A1 (0.57) ALDH1A1TP53TYRTSHRTAS2R38
SCHEMBL30394839 0.89 MAPT (0.58) ALDH1A1MAPTPKMKDM4EKMT2A
Niacinamide SCHEMBL29118200 0.87 F7 (0.67) ALDH1A1PKMNPC1RAB9ALMNA
SCHEMBL9383012 0.85 PKM (0.56) ALDH1A1ATG4BMAPTPKMNPC1
SCHEMBL805874 0.84 LMNA (0.57) ALDH1A1TAS2R38ATG4BMAPTPKM
SCHEMBL15510403 0.83 MAPT (0.74) ALDH1A1MAPTPKMKDM4ELMNA
Methane SCHEMBL11836732 0.83 PKM (0.54) ALDH1A1ATG4BMAPTPKMNPC1
SCHEMBL23220314 0.81 MAPT (0.61) ALDH1A1MAPTPKMKDM4EKMT2A
SCHEMBL162008 0.80 RAB9A (0.65) ALDH1A1TP53HSD17B10MAPTPKM
SCHEMBL14392134 0.80 RAB9A (0.55) ALDH1A1TP53MAPTPKMNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119900058-A Copper plating solution, metal copper layer comprising copper plating solution and application of copper plating solution 江阴纳力新材料科技有限公司 2025-04-29 CN claimed
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US claimed
US-20240092773-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES UCB Biopharma SRL (BE) 2024-03-21 US claimed
CN-115449136-B Accelerator composition of rubber nanocomposite as well as preparation method and application thereof 浙江大学 2024-02-27 CN claimed
US-20230192646-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES UCB Biopharma SRL (BE) 2023-06-22 US claimed
CN-114432901-B Composite membrane with acid resistance and alkali resistance as well as preparation method and application thereof 中国石油化工股份有限公司 2023-04-11 CN claimed
CN-115449136-A Accelerator composition of rubber nanocomposite and preparation method and application thereof 浙江大学 2022-12-09 CN claimed
EP-4081299-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES UCB Biopharma SRL (BE) 2022-11-02 EP claimed
CN-114980975-A Dihydrocyclopentaisoquinoline sulfonamide derivatives UCB生物制药有限责任公司 2022-08-30 CN claimed
CN-114867525-A Dihydrocyclopentaisoquinoline derivatives UCB生物制药有限责任公司 2022-08-05 CN claimed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO claimed
CN-103103587-B Containing the copper electroplating solution of sulfhydryl heterocycle compound SHAANXI NORMAL UNIVERSITY (CN) 2016-02-17 CN claimed
CN-101687816-A Triaminopyrimidine derivatives as the CDC25 inhibitors of phosphatases IPSEN PHARMA SAS 2010-03-31 CN claimed
US-7494815-B2 Method and apparatus for analyzing compounds with amino group AJINOMOTO CO., INC. (JP) 2009-02-24 US claimed
US-20070269899-A1 METHOD AND APPARATUS FOR ANALYZING COMPOUNDS WITH AMINO GROUP AJINOMOTO CO. INC. (JP) 2007-11-22 US claimed
EP-1750126-A1 METHOD AND APPARATUS FOR ANALYZING AMINOFUNCTIONAL COMPOUND Ajinomoto Co., Inc. (JP) 2007-02-07 EP claimed
CN-1181070-C Urea substituted imidazoquinolines 3M 2004-12-22 CN claimed
EP-1198232-A4 UREA SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO (US) 2002-07-24 EP claimed
EP-1198232-A1 UREA SUBSTITUTED IMIDAZOQUINOLINES 3M Innovative Properties Company (US) 2002-04-24 EP claimed
WO-2000076518-A1 UREA SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-12-21 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092773-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES FCER2, FCGR2A, FCGR1A ALDH1A1 1920/4885TP53 3342/4885TYR 1711/4885
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 ALDH1A1 233/4885TP53 2515/4885TYR 179/4885
US-20230192646-A1 DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES FCER2, FCGR2A, FCGR1A ALDH1A1 1433/4885TP53 2636/4885TYR 1829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.